168 related articles for article (PubMed ID: 28978863)
1. [Myeloid neoplasms in the World Health Organization 2016 classification].
Asou N
Rinsho Ketsueki; 2017; 58(10):2178-2187. PubMed ID: 28978863
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.
Patel U; Luthra R; Medeiros LJ; Patel KP
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S62-S74. PubMed ID: 28760304
[TBL] [Abstract][Full Text] [Related]
3. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Arber DA; Orazi A; Hasserjian R; Thiele J; Borowitz MJ; Le Beau MM; Bloomfield CD; Cazzola M; Vardiman JW
Blood; 2016 May; 127(20):2391-405. PubMed ID: 27069254
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
Ungerstedt JS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
[TBL] [Abstract][Full Text] [Related]
5. [Mutations of epigenetic regulator genes and myeloid malignancies].
Muto T; Sashida G; Oshima M; Iwama A
Rinsho Ketsueki; 2015 Nov; 56(11):2287-94. PubMed ID: 26666714
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
7. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
8. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
9. Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.
Prick J; de Haan G; Green AR; Kent DG
Exp Hematol; 2014 Oct; 42(10):841-51. PubMed ID: 25201757
[TBL] [Abstract][Full Text] [Related]
10. Childhood and adolescent lymphoid and myeloid leukemia.
Pui CH; Schrappe M; Ribeiro RC; Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2004; ():118-45. PubMed ID: 15561680
[TBL] [Abstract][Full Text] [Related]
11. Cohesin mutations in myeloid malignancies.
Jann JC; Tothova Z
Blood; 2021 Aug; 138(8):649-661. PubMed ID: 34157074
[TBL] [Abstract][Full Text] [Related]
12. The role of mutations in epigenetic regulators in myeloid malignancies.
Woods BA; Levine RL
Immunol Rev; 2015 Jan; 263(1):22-35. PubMed ID: 25510269
[TBL] [Abstract][Full Text] [Related]
13. [Classification of myeloid leukemias].
Kuriyama K
Nihon Rinsho; 2009 Oct; 67(10):1853-62. PubMed ID: 19860179
[TBL] [Abstract][Full Text] [Related]
14. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
15. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
16. Pathology consultation on myeloproliferative neoplasms.
Schmidt AE; Oh ST;
Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
[TBL] [Abstract][Full Text] [Related]
17. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Rampal R; Levine RL
Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
Jost E; do O N; Dahl E; Maintz CE; Jousten P; Habets L; Wilop S; Herman JG; Osieka R; Galm O
Leukemia; 2007 Mar; 21(3):505-10. PubMed ID: 17230231
[TBL] [Abstract][Full Text] [Related]
19. The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications.
Malcovati L; Ambaglio I; Elena C
Curr Opin Oncol; 2015 Nov; 27(6):551-9. PubMed ID: 26352542
[TBL] [Abstract][Full Text] [Related]
20. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
